Loading…
← CockpitCompetitor Analysis › IRWD Ironwood Pharmaceuticals, Inc. Class AOpen in the cockpit ↗

Ironwood Pharmaceuticals, Inc. Class AIRWDCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum leader 92
Mkt cap
$791M
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$11.1M
20-day average traded
Fwd P/E
3.5×
forward earnings
ROIC−WACC
+123.9 pp
WACC 6.3%
Hurdle
n/a
no reverse DCF
Next earnings
92 days
18 Feb 2027
Close · USD$4.78
1D-1.9%
1W-1.9%
1M+31.7%
3M+15.5%
6M+21.9%
YTD+41.8%
1Y+52.7%
ATR %4.6%
Beta1.40
52w lowhigh17.3% off high

What Ironwood Pharmaceuticals does

Employees: 100

Ironwood Pharmaceuticals at a glance

Size Ironwood Pharmaceuticals (IRWD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $791M, the 2376th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.78 on 18 Nov 2026.

Performance Over six months the shares gained 21.9%, against -7.5% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 19 in its peer set.

Growth Revenue grew 18.1% over the last twelve months (peer median +2.1%); the operating margin is 62.8% (peer median 6.9%).

Valuation It trades at 3.5× forward earnings against a peer median of 19.6× (cheapest of 8).

Capital Return on invested capital runs 123.9 points above its cost of capital (6.3% WACC).

Short interest Short interest is 9.0% of the free float (30 Oct 2026).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026IRWD 124Peer median 93
Six months, rebased to 100: Ironwood Pharmaceuticals against the median of its 20 peers (local-currency closes).

Ironwood Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$400M$296M$351M$443M$411M
Revenue growth—-16%-21%+8%—
Gross profit$398M$294M$349M$441M$409M
EBITDA$253M$121M$97.7M$211M$252M
Net income$150M$24.0M$880,000-$1.00B$175M
Free cash flow$205M$127M$103M$183M$274M
Capital expenditure-$1,000$34,000$142,000$273,000$136,000
Total debt$336M$598M$599M$716M$416M

Quarterly statements and history in the cockpit →

Ironwood Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%GUDORICSANOFI002349ARDX000411RIGL688073SUVENBLISSGVSCOLL60783001002082603229IRWD6-month return →1-month return →
Up and to the right = strong over both horizons. Ironwood Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×100×200×GUDSANOFIARDXRIGL688073COLL6078IRWDRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ironwood Pharmaceuticals is the large dot.

Ironwood Pharmaceuticals competitors and peer comparison

How Ironwood Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ironwood Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureIRWDPeer medianRank in peer set
1-month return+31.7%-2.9%highest of 19
6-month return+21.9%-7.5%5th highest of 19
Distance from 52-week high-17.3%-32.8%4th highest of 19
Revenue growth (TTM)+18.1%+2.1%4th highest of 19
Operating margin62.8%6.9%highest of 19
Forward P/E3.5×19.6×cheapest of 8
ROIC minus cost of capital+123.9 pp-1.9 pphighest of 18
EV / EBITDA4.1×10.4×cheapest of 8
Net debt / EBITDA1.0×-0.5×3rd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%3.5×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%42.2×6.6%+17.7%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%19.6×16.3%-8.7%
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%n/a-2.5%+2.6%
Ardelyx ARDXUnited States$784M-50%+18%-8%252.9×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%n/an/an/a
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%10.8×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%24.3×13.9%+27.7%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%n/an/an/a
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%n/a33.9%+10.1%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%3.7×-2.6%+20.3%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%n/a0.3%+0.5%
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a

Questions

Which companies are Ironwood Pharmaceuticals's closest peers?
The cockpit's peer set: Bambusa Therapeutics (BBTX), Knight Therapeutics (GUD.TO), Oric Pharmaceuticals (ORIC), Sanofi India (SANOFI.NS), Jinghua Pharmaceutical (002349.SZ), Ardelyx (ARDX), Zhejiang Int'l (000411.SZ), Rigel Pharmaceuticals (RIGL).
Is Ironwood Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 3.5× against a peer median of 19.6×, cheapest of 8 in its peer set.
How has Ironwood Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +21.9% against -7.5% for the median peer; over one year +52.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.